Related Experiment Video
Updated: Mar 22, 2026
A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies
Published on: March 8, 2014
Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management
Kosei Nakajima1,2, Dong Hyo Kho1,2, Takashi Yanagawa3
1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, 48201, USA.
Abstract:
The skeleton is frequently a secondary growth site of disseminated cancers, often leading to painful and devastating clinical outcomes. Metastatic cancer distorts bone marrow homeostasis through tumor-derived factors, which shapes different bone tumor microenvironments depending on the tumor cells' origin. Here, we propose a novel insight on tumor-secreted Galectin-3 (Gal-3) that controls the induction of an inflammatory cascade, differentiation of osteoblasts, osteoclasts, and bone marrow cells, resulting in bone destruction and therapeutic failure. In the approaching era of personalized medicine, the current treatment modalities targeting bone metastatic environments are provided to the patient with limited consideration of the cancer cells' origin. Our new outlook suggests delivering individual tumor microenvironment treatments based on the expression level/activity/functionality of tumor-derived factors, rather than utilizing a commonly shared therapeutic umbrella. The notion of "Gal-3-associated bone remodeling" could be the first step toward a specific personalized therapy for each cancer type generating a different bone niche in patients afflicted with non-curable bone metastasis.
Insights
This study reveals Galectin-3 (Gal-3) drives bone destruction in metastatic cancer by altering bone marrow cells. Targeting Gal-3 offers a personalized therapy approach for bone metastasis, improving treatment outcomes.
Area of Science:
- Oncology
- Bone Biology
- Immunology
Background:
- Skeletal metastases cause significant morbidity and therapeutic challenges.
- Tumor-derived factors critically influence the bone tumor microenvironment.
- Current treatments for bone metastases lack personalization based on cancer origin.
Purpose of the Study:
- To elucidate the role of tumor-secreted Galectin-3 (Gal-3) in bone metastasis.
- To propose a novel, personalized therapeutic strategy for bone metastases.
- To introduce the concept of 'Gal-3-associated bone remodeling'.
Main Methods:
- Analysis of tumor-secreted factors and their impact on bone microenvironment.
- Investigation of Gal-3's role in inflammatory cascades and cell differentiation.
- Evaluation of current treatment modalities for bone metastases.
Main Results:
- Tumor-secreted Gal-3 induces inflammation and aberrant differentiation of bone cells (osteoblasts and osteoclasts).
- This process leads to bone destruction and contributes to therapeutic failure.
- Gal-3 significantly impacts bone marrow homeostasis.
Conclusions:
- Gal-3 is a key mediator of bone destruction in metastatic cancer.
- Personalized therapies targeting specific tumor-derived factors like Gal-3 are needed.
- 'Gal-3-associated bone remodeling' offers a pathway for tailored treatments in bone metastasis.
Related Concept Videos
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment